Netherlands· NL-64c2b9175f52
Gliclazide retard Teva 60 mg, tabletten met gereguleerde afgifte
A gliclazide product containing gliclazide, registered in Netherlands by Teva B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Gliclazide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BB09 (gliclazide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Gliclazide · ATC A10BB09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of gliclazide costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.11 in France to $0.61 in Switzerland — a ×5.5 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gliclazide · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.61
- IT Italy$0.26
- FR France$0.11
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GLICLAZIDE
- Manufacturer
- Teva B.V.
- Country
- Netherlands (NL)
- ATC code
- A10BB09
- ATC class
- Gliclazide
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id134037
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for gliclazide.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gliclazide · interactions on record
5 records
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Gliclazide in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDIAPREL MRLes Laboratoires Servier, Suresnes cedex
- PolandClaziconSynoptis Pharma Sp. z o.o.
- FranceDIAMICRON 60 mg, comprimé sécable à libération modifiéeLES LABORATOIRES SERVIER
- SpainDIAMICRON 60 mg COMPRIMIDOS DE LIBERACION MODIFICADALes Laboratoires Servier
- ItalyDIAMICRONMEDIFARM S.R.L.
- United KingdomBilxona 60mg modified-release tabletsActavis UK Ltd
- CanadaAG-GLICLAZIDE MRANGITA PHARMA INC.
- BelgiumGliclazide Lupin 60 mgLupin (Europe)
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Diamicron Mr, Gliclada
- Belgium · Gliclazide Sandoz, Uni Diamicron
- Bulgaria · Гликлада, Диаб
- Cyprus · Diamicron, Glicron
- Czechia · Diaprel Mr, Gliclazid Viatris
- Germany · Diamicron Uno, Glibemat
- Denmark · Diamicron Uno, Gliclazid Krka
- Estonia · Diaprel, Diaprel Mr
- Spain · Diamicron, Gliclazida Aurovitas
- France · Diamicron, Diamicron 60 Mg
- United Kingdom (Northern Ireland) · Dacadis Mr, Diamicron
- Greece · Diamicron, Diamicron Mr
- Croatia · Diaprel Mr, Gliclada
- Hungary · Diaprel Mr, Gliclada
- Ireland · Diaclide Mr, Diacronal Mr
- Iceland · Diamicron Uno, Gliclatim
- Italy · Diamicron, Dramion
- Lithuania · Diaprel Mr, Gliclada
- Luxembourg · Diamicron, Uni Gliclazide Eg
- Latvia · Diaprel Mr, Gliclada
- Malta · Diamicron, Gliclazide Bp Accord Healthcare
- Poland · Clazicon, Diabrezide
- Portugal · Diamicron Lm, Gliclazida Alter
- Romania · Diaprel Mr, Gliclazide Gemax Pharma
- Slovenia · Diaprel, Diaprel Mr
- Slovakia · Diaprel Mr, Gliclada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2a543eb-5270-4fde-968e-09b2da0d164c GET /v1/drugs/f2a543eb-5270-4fde-968e-09b2da0d164c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet met gereguleerde afgifte",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h134037_smpc.pdf",
"strength": null,
"atc_label": "Gliclazide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg134037",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"HYPROMELLOSE 2208, K100 (E 464)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"SILICIUMDIOXIDE (E 551)"
],
"substances": [
"GLICLAZIDE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h134037.pdf",
"authorised_at": "2026/04/07",
"procedure_number": "NL/H/6037/002",
"dispensing_status": "Uitsluitend recept",
"registration_number": "134037",
"additional_monitoring": "N"
}See everything about gliclazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.